Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457210 | PMC |
| http://dx.doi.org/10.1084/jem.2022072908182023c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
Eur J Cancer
November 2024
University of Perugia, Unit of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.
View Article and Find Full Text PDFCorrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma.
Front Oncol
December 2024
Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
[This corrects the article DOI: 10.3389/fonc.2024.
View Article and Find Full Text PDFAn Unusual, Symmetric Rash on Both Forearms in a 94-Year-Old Patient A Clinicopathological Challenge and Diagnostic Pitfall.
J Cutan Pathol
December 2024
Department of Dermatology, University Hospital Basel, Basel, Switzerland.
Article Synopsis
- Trichophyton rubrum (T. rubrum) typically causes minor skin infections, mostly affecting healthy individuals, but can lead to serious infections in immunocompromised patients.
- A unique case involved a 94-year-old man with an invasive T. rubrum infection on both forearms, which resembled cutaneous blastomycosis.
- Diagnosis is complicated as T. rubrum can present with large spore-like structures that mimic Blastomyces dermatitidis, underscoring the necessity for culture or PCR testing for accurate identification.
Mechanism of PD-1/PD-L1 in Regulating cTfr/cTfh Balance in Patients with Rheumatoid Arthritis.
Iran J Allergy Asthma Immunol
October 2024
Department of Ultrasound, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Rheumatoid arthritis (RA) is frequent, an imbalance between helper cells (Th) and regulatory T cells (Treg) is the fundamental immunological cause of RA. This study investigates how recombinant human programmed cell death 1 (PD-L1) protein affects circulating T follicular helper (cTfh), circulating T follicular regulatory (cTfr), and their equilibrium. Magnetic bead sorting was used to select CD4+CXCR5+T cells from RA patients' and healthy individuals' peripheral blood mononuclear cells for in vitro growth.
View Article and Find Full Text PDFDevelopment of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction.
Front Endocrinol (Lausanne)
November 2024
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Background: Immune-related adverse events (irAEs) are reported to be associated with better overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors. However, there may be a bias in that patients who develop irAEs must survive long enough to experience the irAEs, and no prospective studies adjusting for immortal time bias (ITB) have examined the relationship between OS and pituitary dysfunction or the two different types of thyroid dysfunction: destructive thyroiditis and hypothyroidism without prior thyrotoxicosis (isolated hypothyroidism).
Methods: Patients with NSCLC who received nivolumab or pembrolizumab at Nagoya University Hospital between November 2, 2015 and February 1, 2023 were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!